One clinical trial of retrovirally transduced NY-ESO-1 TCR T cells with interleukin (IL)−2 treatment (NCT00670748) demonstrated objective clinical responses in 61% of patients with SS9, and study NCT01343043 identified antitumor responses in up to 50% of advanced SS patients treated with lete-cel7. This evidence concerns the gene CTAG1B and synovial sarcoma.